- Home
- GRND vs RCKT Comparison
GRND vs RCKT Comparison
Compare GRND & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRND
- RCKT
- Stock Information
- Founded
- GRND 2009
- RCKT 1999
- Country
- GRND United States
- RCKT United States
- Employees
- GRND N/A
- RCKT N/A
- Industry
- GRND Computer Software: Prepackaged Software
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- GRND Technology
- RCKT Health Care
- Exchange
- GRND Nasdaq
- RCKT Nasdaq
- Market Cap
- GRND 3.2B
- RCKT 328.6M
- IPO Year
- GRND N/A
- RCKT N/A
- Fundamental
- Price
- GRND $15.86
- RCKT $3.17
- Analyst Decision
- GRND Strong Buy
- RCKT Buy
- Analyst Count
- GRND 6
- RCKT 13
- Target Price
- GRND $21.83
- RCKT $12.96
- AVG Volume (30 Days)
- GRND 1.8M
- RCKT 2.8M
- Earning Date
- GRND 11-06-2025
- RCKT 11-06-2025
- Dividend Yield
- GRND N/A
- RCKT N/A
- EPS Growth
- GRND N/A
- RCKT N/A
- EPS
- GRND N/A
- RCKT N/A
- Revenue
- GRND $385,104,000.00
- RCKT N/A
- Revenue This Year
- GRND $28.55
- RCKT N/A
- Revenue Next Year
- GRND $22.69
- RCKT $108.43
- P/E Ratio
- GRND N/A
- RCKT N/A
- Revenue Growth
- GRND 28.35
- RCKT N/A
- 52 Week Low
- GRND $11.51
- RCKT $2.19
- 52 Week High
- GRND $25.13
- RCKT $22.00
- Technical
- Relative Strength Index (RSI)
- GRND 46.17
- RCKT 48.10
- Support Level
- GRND $15.31
- RCKT $3.09
- Resistance Level
- GRND $16.36
- RCKT $3.29
- Average True Range (ATR)
- GRND 0.52
- RCKT 0.15
- MACD
- GRND 0.17
- RCKT -0.02
- Stochastic Oscillator
- GRND 71.31
- RCKT 37.94
About GRND Grindr Inc.
Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.